SEC Form 4 · accession 0001171843-17-006079
Anika Therapeutics, Inc. · ANIK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles H Sherwood
Officer — CEO and Director · Director
Period of report
Oct 12, 2017
Accepted (ET)
Oct 16, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000898437
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 12, 2017 | S | 1,908 | $60.00 | D | 172,797 | D | |
| Common StockF2 | Oct 13, 2017 | S | 5,216 | $60.11 | D | 167,581 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On October 12, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 1,908 shares in a single trade at $60.00.
- F2On October 13, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,216 shares in multiple trades ranging from $60.00 to $60.17. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected.